TREAT 005: Effect of heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling
Enrolling: Yes
Principal Investigator: Dr. Naga Chalasani
Duration: 6 weeks total, with 4 weeks on treatment
Primary Outcomes measured: Change in bile salt metabolism levels to determine effect of FXR; change in FGF19 levels to determine effect of FXR
Drug(s): obeticholic acid tablet or placebo
|
Contact:
Jennifer Lehman
(317) 278-1872
jgeck@iu.edu
|
Hepatic Adenoma Biorepository
Enrolling: Yes
Principle Investigator: Dr. Craig Lammert
Duration: 1 visit
Patient Population: Hepatic adenoma with history of oral contraceptive use.
|
Contact:
Kelsey Green
(317) 278-9292
greenke@iu.edu
|
Cystic Fibrosis
Enrolling: Yes
Principle Investigator: Dr. Naga Chalasani
Duration: 1 visit
Patient Population: Aged 18 or greater with cystic fibrosis.
|
Contact:
Regina Weber
(317) 278-3584
reginaw@iu.edu
|
Fibroscan Database
Enrolling: Yes
Duration: 1 visit
|
Contact:
Regina Weber
(317) 278-3584
reginaw@iu.edu
|
Liver Biopsy Collection for Future Research
Enrolling: Yes
Principle Investigator: Dr. Naga Chalasani
Duration: 1 visit |
Contact:
Allison White
(317) 278-6266
whitalli@iu.edu
|